REPORTING OF CARDIOVASCULAR EVENTS IN CLINICAL TRIALS SUPPORTING FDA-APPROVAL OF CONTEMPORARY CANCER DRUGS

被引：1

作者：

Addison, Daniel ^{[1
]}

Bonsu, Janice ^{[1
]}

Charles, Lawrence ^{[1
]}

Guha, Avirup ^{[1
]}

Baker, Brandee ^{[1
]}

Woyach, Jennifer ^{[1
]}

Awan, Farrukh ^{[1
]}

Rogers, Kerry ^{[1
]}

Lustberg, Maryam ^{[1
]}

Reinbolt, Raquel ^{[1
]}

Brammer, Jonathan ^{[1
]}

Miller, Eric ^{[1
]}

Jneid, Hani ^{[1
]}

Paskett, Electra ^{[1
]}

机构：

[1] Ohio State Univ, Columbus, OH 43210 USA

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2019年 / 73卷 / 09期

关键词：

D O I：

10.1016/S0735-1097(19)32485-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1331-429

引用

页码：1879 / 1879

页数：1

共 50 条

[31] Participation of African American Persons in Clinical Trials Supporting US Food and Drug Administration Approval of Cancer Drugs
Al Hadidi, Samer
Mims, Martha
Miller-Chism, Courtney Nicole
Kamble, Rammurti
ANNALS OF INTERNAL MEDICINE, 2020, 173 (04) : 320 - +
[32] CARDIOVASCULAR SAFETY REPORTING IN BREAST CANCER CLINICAL TRIALS
Hamid, A.
Ruckdeschel, J.
Khan, M. S.
Tharwani, A.
Oshunbade, A. A.
Kipchumba, R. K.
Thigpen, C.
Anker, S. D.
Fonarow, G. C.
Hall, M. E.
Butler, J.
JOURNAL OF INVESTIGATIVE MEDICINE, 2021, 69 (02) : 493 - 493
[33] Characteristics of Trials Preceding FDA Approval of Novel Psychiatric Drugs
Ahn-Horst, Rosa Y.
Turner, Erick H.
Kesselheim, Aaron S.
JAMA NETWORK OPEN, 2025, 8 (01)
[34] Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price
Michaeli, Daniel Tobias
Michaeli, Thomas
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22 (04):
[35] Age-based disparities in clinical trials supporting FDA approval of therapies for solid tumors.
Gajra, Ajeet
Zettler, Marjorie E.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[36] More thoughts on the reporting of adverse events in cancer clinical trials
Extermann, Martine
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) : 918 - 918
[37] Efficacy, innovativeness, clinical trials, endpoints, and price of drugs with FDA approval for non-small cell lung cancer (NSCLC)
Michaeli, C. T.
Michaeli, J. C.
Desai, A.
Albers, S.
Michaeli, D. T.
ANNALS OF ONCOLOGY, 2024, 35 : S845 - S845
[38] Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy
Bossi, Paolo
Botta, Laura
Bironzo, Paolo
Sonetto, Cristina
Musettini, Gianna
Sbrana, Andrea
Di Giannantonio, Valerio
Locati, Laura D.
Di Maio, Massimo
Antonuzzo, Andrea
FUTURE ONCOLOGY, 2019, 15 (21) : 2543 - 2553
[39] Systematic review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy
Antonuzzo, A.
Bossi, P.
Botta, L.
Bironzo, P.
Sonetto, C.
Musettini, G.
Sbrana, A.
Di Giannantonio, V.
Locati, L.
Di Maio, M.
ANNALS OF ONCOLOGY, 2016, 27
[40] Systematic review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy
Bossi, P.
Botta, L.
Bironzo, P.
Sonetto, C.
Musettini, G.
Sbrana, A.
Di Giannantonio, V.
Locati, L.
Di Maio, M.
Antonuzzo, A.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →